Acellular pertussis vaccine comprising a combination of the 69 kDa and the filamentous haemagglutinin antigens of Bordetella pertussis
AssigneeUCB Pharma S.A.
InventorPavel Novotny
Life of this patent
Estimating the term…
Abstract
An acellular vaccine is provided which in use provides protection against Bordetella pertussis infections. The vaccine is based on the synergistic combination of two antigenes from B. pertussis, the 69 kDa, and the filamentous haemagglutinin antigens.
Claims30
An acellular pertussis vaccine comprising a combination of Bordetella pertussis antigens, said combination consisting of isolated and purified 69 kDa antigen of Bordetella pertussis and isolated and purified filamentous haemagglutinin antigen of Bordetella pertussis, wherein the 69 kDa antigen and the filamentous haemagglutinin antigen are present in a ratio of from 1:1 to 1:10, wherein the vaccine is effective in inducing protection in a mammal to subsequent challenge by a virulent strain of Bordetella pertussis.
A method of vaccinating a mammal susceptible to Bordetella pertussis infection comprising administering to the mammal an acellular pertussis vaccine comprising a combination of Bordetella pertussis antigens, said combination consisting of isolated and purified 69 kDa antigen of Bordetella pertussis and isolated and purified filamentous haemagglutinin antigen of Bordetella pertussis, wherein the 69 kDa antigen and the filamentous haemagglutinin antigen are present in a ratio of from 1:1 to 1:10, wherein the vaccine is effective in inducing protection in a mammal to subsequent challenge by a virulent strain of Bordetella pertussis.
A method of formulating an acellular pertussis vaccine comprising (i) a combination of Bordetella pertussis antigens, said combination consisting of isolated and purified 69 kDa antigen of Bordetella pertussis and isolated and purified filamentous haemagglutinin antigen of Bordetella pertussis and (ii) a pharmaceutically acceptable excipient, wherein the 69 kDa antigen and the filamentous haemagglutinin antigen are present in a ratio of from 1:1 to 1:10,
- wherein the method comprises admixing the pharmaceutically acceptable excipient with the combination of the Bordetella pertussis antigens.
Dependencies are inferred from the claim text.